Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 6/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30171448 | 1.00 | MAPT (0.36) | MAPTRXFP1MEN1GAAKMT2A | |
| SCHEMBL24864800 | 0.91 | TP53 (0.35) | MAPTRXFP1MEN1KMT2ATP53 | |
| SCHEMBL24864715 | 0.91 | RECQL (0.37) | MAPTRXFP1MEN1KMT2ATP53 | |
| SCHEMBL24864714 | 0.84 | PARP14 (0.34) | MAPTRXFP1TP53HDAC6TNKS | |
| SCHEMBL24864828 | 0.83 | EGLN1 (0.33) | MAPTRXFP1TP53EGLN1 | |
| SCHEMBL24864827 | 0.81 | EGLN1 (0.31) | EGLN1 | |
| SCHEMBL24864826 | 0.80 | TP53 (0.33) | MAPTRXFP1TP53 | |
| SCHEMBL24864719 | 0.79 | ALDH1A1 (0.40) | MAPTRXFP1MEN1KMT2ATP53 | |
| SCHEMBL24864991 | 0.78 | RECQL (0.36) | MAPTRXFP1MEN1GAAKMT2A | |
| SCHEMBL30171422 | 0.78 | RECQL (0.36) | MAPTRXFP1MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074925-A1 | RARE EARTH COMPLEX | SAGAMI CHEMICAL RESEARCH INSTITUTE (JP) | 2025-03-06 | — | — | US | disclosed |
| EP-4365180-A1 | RARE EARTH COMPLEX | Tosoh Corporation (JP) | 2024-05-08 | — | — | EP | disclosed |
| WO-2023282236-A1 | RARE EARTH COMPLEX | 東ソー株式会社 | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074925-A1 | RARE EARTH COMPLEX | L1CAM, CHRM1, NPM1 | MAPT 3174/4885RXFP1 689/4885MEN1 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.